RNK08954

RNK08954 is an investigational, orally administered small molecule developed by Ranok Therapeutics. It acts as a non-covalent, selective inhibitor and degrader of KRAS G12D, a common oncogenic mutation found in various advanced solid tumors. The drug is currently being evaluated in Phase 1/2 clinical trials for its safety, tolerability, pharmacokinetics, and preliminary anti-tumor efficacy in patients with advanced solid tumors harboring the KRAS G12D mutation. The study includes dose escalation and expansion phases to determine the optimal dosing regimen and assess clinical activity across multiple tumor types such as colorectal cancer and pancreatic adenocarcinoma[1][2][3][4][5].